Protagenic Therapeutics issued a letter regarding Nasdaq non-compliance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 27 2025
0mins
Should l Buy ?
Source: SeekingAlpha
Nasdaq Non-Compliance Notification: Protagenic Therapeutics (PTIX) received a notification from Nasdaq regarding its non-compliance with listing rules, specifically failing to meet the minimum stockholders' equity requirement of $2.5 million and not filing its September 30, 2025 Form 10-Q on time.
Delisting Determination: Due to recent compliance issues and a mandatory monitoring period, Nasdaq has determined to delist the company's securities, prompting PTIX to request a hearing to present its plan to rectify these deficiencies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
